Equity Analyst - Fundamental & Thematic, Sree Capital

Sreemant Dudhoria

Equity Analyst - Fundamental & Thematic

Fundamental Research on Listed Indian Companies

Sree Capital

Sree Capital is a platform to share fundamental research on listed Indian companies. We do this research for our own investment

Equity Bottom-Up

<ul>
<li>51 companies recorded insider acquisitions in September 2026 — the broadest monthly cohort in recent months.</li>
<li>We highlight large and small cap companies that experienced significant insider buying during September 2026, as reported on the stock exchanges.</li>
<li>We also present key sectors which saw insider buying during the month along with names which have moved significantly above/below the insider buying price.</li>
</ul>


51 companies recorded insider acquisitions in September 2026 — the broadest monthly cohort in recent months.
We highlight large and small cap companies that experienced significant insider buying during September 2026, as reported on the stock exchanges.
We also present key sectors which saw insider buying during the month along with names which have moved significantly above/below the insider buying price.


Insider Activity: Who Is Buying Their Own Stock During the Market Correction? – September 2026

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>NIFTY 50 represents the 50 largest stocks listed in the National Stock Exchange (NSE) of India and the NIFTY Next 50 index tracks the next 50 largest names.</li>
<li>Here we have presented our expectations for these indices for the upcoming index rebal event in March 2027.</li>
<li>We see two changes for NIFTY 50 and five changes for NIFTY 100.</li>
</ul>


NIFTY 50 represents the 50 largest stocks listed in the National Stock Exchange (NSE) of India and the NIFTY Next 50 index tracks the next 50 largest names.
Here we have presented our expectations for these indices for the upcoming index rebal event in March 2027.
We see two changes for NIFTY 50 and five changes for NIFTY 100.


Quiddity Leaderboard NIFTY Mar27: Some High-Impact ADDs/DELs; ~US$1.3bn Combined One-Way Flow

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Derivatives

<ul>
<li>Novo committed to scale oral Wegovy manufacturing tenfold by 2030, opening potential peptide overflow work for integrated Indian CDMOs such as Divi’s.</li>
<li>Oral semaglutide is far more peptide-intensive per patient than injectable Wegovy, so capacity scale-up raises demand for fragments, building blocks and cost-efficient CDMO supply.</li>
<li>Treat oral Wegovy as optionality only; Lilly tirzepatide remains Divi’s core peptide opportunity, and Divi’s stays our top India Pharma pick.</li>
</ul>


Novo committed to scale oral Wegovy manufacturing tenfold by 2030, opening potential peptide overflow work for integrated Indian CDMOs such as Divi’s.
Oral semaglutide is far more peptide-intensive per patient than injectable Wegovy, so capacity scale-up raises demand for fragments, building blocks and cost-efficient CDMO supply.
Treat oral Wegovy as optionality only; Lilly tirzepatide remains Divi’s core peptide opportunity, and Divi’s stays our top India Pharma pick.


Divi’s Labs: Oral Wegovy Scale-Up, New Optionality

<ul>
<li>Just 14 companies reported insider acquisitions in July2026. Aggregate transaction value was just INR280 million—a materially lower absolute figure than June 2026(INR 6 billion),largely because July being a silent period.</li>
<li>We highlight large and small cap companies that experienced significant insider buying during July 2026, as reported on the stock exchanges.</li>
<li>We also present key sectors which saw insider buying during the month along with names which have moved significantly above the insider buying price.</li>
</ul>


Just 14 companies reported insider acquisitions in July2026. Aggregate transaction value was just INR280 million—a materially lower absolute figure than June 2026(INR 6 billion),largely because July being a silent period.
We highlight large and small cap companies that experienced significant insider buying during July 2026, as reported on the stock exchanges.
We also present key sectors which saw insider buying during the month along with names which have moved significantly above the insider buying price.


Insider Activity: Who Bought Their Own Stock in July 2026 ?

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Thematic (Sector/Industry)

<ul>
<li>On<strong> 20th March 2026,</strong> the critical patent for Semaglutide expires in India, decisively ending the innovator's legal monopoly and enabling highly affordable generic versions. </li>
<li>This triggers a <strong>massive 70% retail price drop</strong> in India, exponentially expanding affordable access to millions suffering from prevalent obesity and diabetes.</li>
<li>Vertically integrated formulators like Sun Pharma and specialized API manufacturers like Divis Laboratories capture maximum alpha through scaled volumes and zero customer acquisition costs.</li>
</ul>


On 20th March 2026, the critical patent for Semaglutide expires in India, decisively ending the innovator's legal monopoly and enabling highly affordable generic versions. 
This triggers a massive 70% retail price drop in India, exponentially expanding affordable access to millions suffering from prevalent obesity and diabetes.
Vertically integrated formulators like Sun Pharma and specialized API manufacturers like Divis Laboratories capture maximum alpha through scaled volumes and zero customer acquisition costs.


The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

India

Divi's Laboratories Ltd. manufactures pharmaceutical products which include generic drugs and their intermediates. The Company also undertakes contract research activities for other pharmaceutical companies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Divi's Laboratories (DIVI IN)

Insider Activity: Who Is Buying Their Own Stock During the Market Correction? – September 2026

Insight on insider buying in Sep 2026 — the broadest monthly cohort in recent months -highlighting key sectors along with names which have moved...

Sreemant Dudhoria

Quiddity Leaderboard NIFTY Mar27: Some High-Impact ADDs/DELs; ~US$1.3bn Combined One-Way Flow

We expect US$824mn and US$493mn one-way flows for NIFTY 50 and NIFTY Next 50 respectively. The NIFTY 50 expected ADDs/DELs have >8x ADV to trade.

Janaghan Jeyakumar, CFA

Divi’s Labs: Oral Wegovy Scale-Up, New Optionality

On Capital Market day, when Novo announced 10x oral Wegovy scale-up. This is peptide CDMO optionality for Divis Lab, the core GLP-1 bet.

Sudarshan Bhandari

Insider Activity: Who Bought Their Own Stock in July 2026 ?

The last week of August (after the results season and silent period got completed) saw buying from Nava Ltd, Thangamayil Jewellery(multiple...

Sreemant Dudhoria

The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

Nimish Maheshwari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Insider Activity: Who Is Buying Their Own Stock During the Market Correction? – September 2026

Insight on insider buying in Sep 2026 — the broadest monthly cohort in recent months -highlighting key sectors along with names which have moved...

Sreemant Dudhoria

Quiddity Leaderboard NIFTY Mar27: Some High-Impact ADDs/DELs; ~US$1.3bn Combined One-Way Flow

We expect US$824mn and US$493mn one-way flows for NIFTY 50 and NIFTY Next 50 respectively. The NIFTY 50 expected ADDs/DELs have >8x ADV to trade.

Janaghan Jeyakumar, CFA

Divi’s Labs: Oral Wegovy Scale-Up, New Optionality

On Capital Market day, when Novo announced 10x oral Wegovy scale-up. This is peptide CDMO optionality for Divis Lab, the core GLP-1 bet.

Sudarshan Bhandari

Insider Activity: Who Bought Their Own Stock in July 2026 ?

The last week of August (after the results season and silent period got completed) saw buying from Nava Ltd, Thangamayil Jewellery(multiple...

Sreemant Dudhoria

The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

​Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

Nimish Maheshwari

Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.